BioMarin Pharmaceutical (MEX:BMRN) Total Equity: MXN112,021 Mil (As of Mar. 2026)


MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN959.00
GF Value MXN1,495.95
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Total Equity?

BioMarin Pharmaceutical MEX:BMRN 80 Total Equity is MXN112,021 Mil as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,495.95 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMarin Pharmaceutical's total equity for the quarter that ended in Mar. 2026 was MXN112,021 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioMarin Pharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Total Equity Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87,505.93 89,743.13 84,048.82 118,001.34 109,600.68

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118,523.74 113,485.72 111,105.52 109,600.68 112,021.06
MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioMarin Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=136735.682-27135.004
=109,601

BioMarin Pharmaceutical's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=154919.214-42898.152
=112,021

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of MXN112,021 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Total Equity of MXN112,021 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Total Equity too high?
BioMarin Pharmaceutical's current Total Equity is MXN112,021 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Total Equity compare to CYTK and ARWR?
BioMarin Pharmaceutical's Total Equity of MXN112,021 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Total Equity is MXN112,021 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,495.95, compared to a current price of MXN959.00 — trading 35.9% below its estimated fair value. The current Total Equity is MXN112,021 Mil. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Total Equity is MXN112,021 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 35.9% below its estimated GF Value™ of MXN1,495.95. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Total Equity: MXN112,021 Mil
  • GF Value™: MXN1,495.95 vs. price of MXN959.00 (35.9% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,495.95
GF Value